CEO Executive AssistantBiotech CEOs who come from scientific backgrounds face a particularly acute delegation challenge. The depth of their scientific knowledge is simultaneously an organizational asset and a delegation liability. The CEO who can evaluate a binding affinity assay, critique a pharmacokinetics model, or engage substantively with a protein structure hypothesis is tempted to remain deeply embedded in scientific decision-making long after the organization’s scale demands that they step back.
This scientific expertise, deployed at the wrong organizational level, crowds out the strategic and commercial work that only the CEO can perform. It also signals to the scientific team that their independent judgment is not trusted, which undermines the very scientific leadership that drives biotech value creation.
These best practices help biotech CEOs establish a delegation model for their scientific teams that channels executive scientific expertise into high-leverage moments while building the team’s capacity for autonomous, excellent scientific work.
Best Practice 1: Distinguish Scientific Leadership from Scientific Execution
The foundation of biotech CEO delegation to the scientific team is clarity about the difference between scientific leadership and scientific execution. Scientific leadership, meaning the strategic direction of the research portfolio, the decision about which targets to pursue, the prioritization of resources across programs, and the scientific narrative that drives investor and partner confidence, is legitimately a CEO function. Scientific execution, meaning the design and conduct of experiments, the analysis of data, the management of laboratory workflows, and the day-to-day scientific problem-solving, is the scientific team’s domain.
Many biotech CEOs blur this distinction, participating in scientific execution decisions that should belong to the Chief Scientific Officer (CSO) and the research team below. The practical test is simple: if the CEO’s contribution in a scientific discussion is primarily technical rather than strategic, the CEO is likely operating too deep in the execution layer.
Best Practice 2: Invest in the CSO as the Primary Scientific Delegate
The CSO is the CEO’s primary scientific delegate. This relationship is the most important delegation relationship in the scientific domain and deserves significant investment in clarity and trust.
The CSO should have unambiguous authority over: scientific methodology and experimental design across all programs, scientific staffing decisions within the research function, scientific quality standards and laboratory operations, prioritization of scientific resource allocation within the CEO-approved portfolio strategy, and scientific partnerships and collaborations at the working level.
The CEO’s scientific engagement with the research function should primarily flow through the CSO: scientific portfolio reviews conducted with the CSO, scientific strategy discussions that inform the CEO’s investor communications, and major scientific inflection points that have strategic implications. Direct CEO engagement in the lab teams’ work, bypassing the CSO, should be exceptional and conducted with the CSO’s awareness.
Best Practice 3: Establish Scientific Review Rhythms That Work for Delegation
The mechanism that keeps the CEO informed about scientific progress without requiring operational involvement is a structured scientific review cadence. Design this cadence to provide genuine strategic insight without pulling the CEO into execution-level discussions.
A recommended cadence for a biotech company in early clinical development:
Monthly Program Review: Each active program’s CSO or Program Lead presents a one-page summary covering key data generated, hypothesis status, next experiments planned, and any decision points on the horizon. The CEO attends, asks strategic questions, and flags any items requiring strategic response. This is not a detailed data review.
Quarterly Portfolio Review: A deeper review of the full scientific portfolio covering progress against milestones, resource allocation effectiveness, and emerging scientific risks or opportunities. The CEO and CSO co-lead this discussion with the full scientific leadership team.
Annual Science Day: An intensive review of scientific strategy, pipeline priorities, and emerging therapeutic area opportunities. This is where the CEO’s scientific expertise adds the most value: evaluating strategic options and making portfolio-level decisions with full scientific context.
Between these structured reviews, the CEO should receive a brief weekly scientific update from the CSO: one to three paragraphs covering what the team accomplished, any significant results, and any decisions the CSO is making or escalating.
Best Practice 4: Define Escalation Triggers for CEO Scientific Engagement
Not every scientific development requires CEO involvement, but some do. Defining escalation triggers creates a shared understanding of when the CSO should bring something to the CEO’s attention and when they should proceed independently.
Common escalation triggers in biotech scientific management:
- A key study misses its primary endpoint in a way that calls the program’s scientific rationale into question
- An unexpected safety signal emerges in an animal or clinical study
- A scientific breakthrough creates a significant new program opportunity that would require resource reallocation
- A competitor publishes data that materially changes the competitive landscape for a program
- A scientific advisor or key opinion leader raises fundamental questions about the program’s approach
- A manufacturing or formulation problem threatens program timelines
The CSO should handle all scientific developments below these thresholds independently. The CEO’s attention is a scarce resource; escalation triggers ensure it is deployed where it genuinely adds value.
Best Practice 5: Delegate Scientific Communications with Clear Protocols
Biotech organizations communicate scientific progress to multiple audiences: investors, partners, regulatory agencies, scientific advisors, and the public. The CEO typically cannot delegate all scientific communications without compromising organizational credibility, but a clear delegation protocol can significantly reduce the CEO’s communication burden.
Investor scientific communications (earnings calls, investor days, one-on-one meetings with key investors) typically require CEO involvement because investors are evaluating not just the science but the leadership team’s command of it. The CSO can prepare the scientific content; the CEO delivers the narrative.
Partner scientific communications (working-level discussions with potential collaborators, data sharing for due diligence) can often be led by the CSO, with CEO involvement reserved for strategic partnership discussions where organizational authority and relationship investment are the primary value added.
Regulatory scientific communications (IND submissions, FDA meetings, scientific advice meetings) should be led by the medical or regulatory function with appropriate scientific team support, not by the CEO personally.
See pharma CEO delegation guide for a comprehensive framework on how biotech CEOs can structure delegation across all external-facing scientific and commercial communications.
Best Practice 6: Build Individual Scientific Leader Accountability
Below the CSO level, effective delegation requires building individual accountability for scientific team leaders. Program leads, therapeutic area heads, and platform leads should each have clear mandates, defined decision authorities, and measurable scientific milestones.
The performance management system for scientific leaders should be built around scientific milestone achievement, not just scientific effort. A Program Lead who runs a rigorous scientific program that hits its milestones is performing well even if the scientific results are not always positive. A Program Lead whose program consistently falls behind on data generation or whose experimental designs are not robust is not performing well regardless of how hard the team is working.
The CEO’s role in scientific leadership accountability is to hold the CSO accountable for the scientific team’s overall performance, and to engage directly with individual scientific leaders primarily in strategic contexts (program reviews, science day) rather than operational ones.
Best Practice 7: Protect Scientific Team Autonomy
One of the most important delegation best practices for biotech CEOs is actively protecting the scientific team’s autonomy. When scientific leaders believe the CEO will second-guess every experiment or override data-driven conclusions with strategic preferences, scientific decision-making becomes politicized. Scientists spend time managing upward rather than designing rigorous experiments. The quality of scientific thinking suffers.
Protect scientific autonomy by: committing publicly to letting data drive program decisions, explicitly acknowledging when the scientific team’s judgment overrides your own initial instinct, and resisting the temptation to override scientific conclusions based on investor relations or strategic positioning concerns.
According to McKinsey research on biotech R&D productivity, biotech companies with strong scientific leadership structures, meaning CEOs who empower their scientific teams to make data-driven decisions, outperform those where scientific decision-making is concentrated at the CEO level. Scientific autonomy within a clear strategic framework is a value driver, not a governance risk.
For context on how scientific team delegation connects to the broader clinical operations management structure, see pharma CEO clinical ops, which covers how delegation across research and clinical functions can be coordinated effectively.
Best Practice 8: Evolve the Delegation Model as the Company Matures
The appropriate delegation model for a 15-person preclinical biotech is very different from the model for a 300-person company with multiple programs in clinical development. As the organization grows, the CEO’s scientific involvement should naturally compress and the CSO’s leadership role should expand.
Plan this evolution intentionally. Define, at each stage of company development, what the CEO’s scientific role should look like and what should fully belong to the scientific team. Resist the tendency to maintain scientific depth habits from earlier stages when they are no longer appropriate for the current scale.
The biotech CEO who successfully builds a delegation model for the scientific team creates organizational capacity for scientific excellence that scales beyond any individual’s expertise. That is the true measure of delegation success.
Related Reading
For further context, explore Delegation Best Practices for AgTech Startup CEOs and Delegation Best Practices for Cloud Company CEOs.